New Zealand missed the boat on medical cannabis and is too late to the game to gain a serious foothold in the commodity space, according to Nubu Pharmaceuticals.
The medical cannabis company is in the midst of a $2.5 million series A funding round for 12.5% of the company at a pre-money
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
